Treatment of macular degeneration with ADP-ribosyl...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S013300, C424S094500, C435S069700

Reexamination Certificate

active

07910554

ABSTRACT:
The Rho family of GTPases regulates axon growth and regeneration. Inactivation of Rho with C3, a toxin fromClostridium botulinum, can stimulate regeneration and sprouting of injured axons. The present invention provides novel chimeric C3-like Rho antagonists. These new antagonists are a significant improvement over C3 compounds because they are 3-4 orders of magnitude more potent to stimulate axon growth on inhibitory substrates than recombinant C3. The invention further provides methods of treating a disease of the eye by administering the compounds of the invention.

REFERENCES:
patent: 5393739 (1995-02-01), Bentz et al.
patent: 5652122 (1997-07-01), Frankel et al.
patent: 5670617 (1997-09-01), Frankel et al.
patent: 5674980 (1997-10-01), Frankel et al.
patent: 5747641 (1998-05-01), Frankel et al.
patent: 5804604 (1998-09-01), Frankel et al.
patent: 5945290 (1999-08-01), Cowsert
patent: 6855688 (2005-02-01), McKerracher
patent: 7442686 (2008-10-01), Lasko et al.
patent: 2002/0032148 (2002-03-01), Uehata et al.
patent: 2002/0077283 (2002-06-01), Sessa
patent: 2003/0103957 (2003-06-01), McKerracher et al.
patent: 2005/0059595 (2005-03-01), Lasko et al.
patent: 2007/0270340 (2007-11-01), McKerracher et al.
patent: 2008/0269120 (2008-10-01), McKerracher et al.
patent: 2300878 (1999-02-01), None
patent: 2304981 (1999-05-01), None
patent: 2301157 (1999-11-01), None
patent: 2342970 AA (2002-10-01), None
patent: 585168 (1994-03-01), None
patent: 1177796 (2002-06-01), None
patent: WO 97/23236 (1997-07-01), None
patent: WO 99/23113 (1999-05-01), None
patent: 2005030248 (2005-04-01), None
patent: WO 2005/030248 (2005-04-01), None
patent: 2008022182 (2008-02-01), None
Wilde et al., Toxicon, 2001, vol. 39(11):1647-1660.
Borras, Exp. Eye Res., 2003, vol. 76, pp. 643-652.
Kimura et al., Adv. Drug Deliv. Rev., 2001, vol. 52(1):79-91.
ISR, Jul. 3, 2008.
ISR, Mar. 21, 2003.
Adler et al., Cell death in age-related macular degeneration, Molecular Vision, 1999: 5:31, pp. 31-36.
Curcio et al., Photoreceptor loss in age-related macular degeneration, Invest Ophthalmol Vis Sci, Jun. 1996;37 (7):1236-49 (Abstract only).
Fan et al., Differential regulation of A beta42-induced neuronal Clq synthesis and microglial activation,J. Neuroinflammation, 2005, 2:1, pp. 1-13.
Hahn et al., Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and . . . , PNAS, 2004, 101:38, pp. 13850-13855.
Klaver et al., Genetic Association of Apolipoprotein E with Age-Related Macular Degeneration, Am. J. Hum Genet.. 1998, 63:200-206.
Medeiros et al., Preservation of Ganglion Cell Layer Neurons in Age-related Macular Degeneration, Investigative Ophthalmology & Visual Science, 2001, 42:3, pp. 795-803.
Vander et al., Growth rate of subretinal newvascularization in age-related macumar degeneration, Ophthalmology, 1989, 96(9), pp. 1422-1426. (Abstract only).
E.I. Pecheur et al., Peptides and Membrane Fusion: Towards an Understanding of the Molecular Mechanism of Protein-Induced Fusion, J. Membrane Biol., 1999, 167:1-17, Springer-Verlag New York Inc.
Kazmierczak et al., Rho GTPase activity modulates Pseudomonas aeruginosa internalization by epithelial cells, Cellular Microbiology, 2001, 3:2, pp. 85-98.
Sauzeau et al., Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase, Circulation Research, 2001, 88:11, pp. 1102-1104.
Winton et al., A novel group of permeable Rho antagonists that promote axon regeneration on growth inhibitory substances. Society for Neuroscience Abstracts, 2001, 27:2, p. 2120. (Abstract only).
Lehmann et al., Inactivation of Rho signaling pathway promotes CNS axon regeneration, Journal of Neuroscience, 1999, 19:17, pp. 7537-7547.
Folkman et al., J. Biol. Chem. (1992), pp. 10931-10934, vol. 267.
Rojas et al., Nature Biotechnology (1998), pp. 370-375, vol. 16.
Vives et al., The Journal of Biological Chemistry (1997), pp. 16010-16017, vol. 272, No. 25.
Wender et al., Proc. Nat'l Acad. Sci, USA (2000), pp. 13003-13008, vol. 97, No. 24.
Derossi et al., The Journal of Biological Chemistry (1996), pp. 18188-18193, vol. 271, No. 30.
Wilde et al., The Journal of Biological Chemistry (2001), pp. 9537-9542, vol. 276, No. 12.
Aullo et al., The EMBO Journal (1993), pp. 921-931, vol. 12, No. 3.
Bloch-Gallego et al., The Journal of Cell Biological Chemistry (1993), pp. 485-492, vol. 120, No. 2.
Derossi et al., The Journal of Biological Chemistry (1994), pp. 10444-10450, vol. 269, No. 14.
Verschuren, H. et al., European Journal of Cell Biology (1997), pp. 182-187, vol. 73.
Imamura, F. et al., Jpn. J. Cancer Res. (2000), pp. 811-816, vol. 91.
Yoshioka, K. et al., FEBS Letters (1995), pp. 25-28, vol. 372.
Van Aelst, L. et al., Genes & Development (1997), pp. 2295-2322, vol. 11.
Wilde, C. et al., Journal of Biological Chemistry (2000), pp. 16478-16483, vol. 275, No. 22.
Aktories, K. et al., Trends in Cell Biology (1995), pp. 441-443, vol. 5.
Kemp , C.M. et al., Investigative Ophthalmology & Visual Science (1994), pp. 3154-3162, vol. 35. No. 8.
Dalke, C. et al., Experimental Eye Research (2005), pp. 503-512, vol. 81.
Winton, M.J. et al., Journal of Biological Chemistry (2002), pp. 32820-32829, Vo. 277.
Hirai, F. et al., Biochemical and Biophysical Research Communications (2007), vol. 356: 279-285.
Singh, A.T., et al., Endocrinology (2005), vol. 146(5): 2171-2175.
Majumder et al., J. Biol. Chem (1998), vol. 273(17), pp. 10099-10106.
Van Golen, et al., Neoplasia (2000), vol. 2(5), pp. 418-425.
Park, et al., Circ. Res. (2002), vol. 91(2), pp. 143-50.
Cleverly, et al., Oncogene (2000), vol. 19, pp. 13-20.
Moorman, et al., J. lmmunol. (1996). vol. 156(1), pp. 4146-4153.
Burger, J. Neuro-Oncology (1995), vol. 24, pp. 3-7.
Classification of Cancer—Grading, Staging, www.oncologychannel.com—published Sep. 1, 2002.
Fawell, et al., PNAS USA (1994), vol. 91, pp. 664-668.
Busca, et al., Mol. Biol. Chem. (1998), vol. 9, pp. 1367-1378.
Forget, et al., Clin. Exp. Metastasis (2002), vol. 19(1), pp. 9-15.
Pecheur, E. I., et al., J. Membrane Biol. (1999), 167:1-17, Springer-Verlag New York Inc.
Adler, et al., Molecular Vision (1999), 5:31, pp. 31-36.
Curcio, et al., Invest. Ophthalmol. Vis. Sci. (1996), Jun.; 37(7): 1236-49 (Abstract only).
Fan, et al., J. Neuroinflammation (2005), 2:1, pp. 1-13.
Hahn, et al., PNAS (2004), 101:38, pp. 13850-13855.
Klaver, et al., AM. J. Hum. Genet. (1998), 63:200-206.
Medeiros, et al., Investigative Ophthalmology & Visual Science (2001), 42:3, pp. 795-803.
Vander, et al., Ophthalmology (1989), 96(9), pp. 1422-1426 (Abstract only).
Ciardella, et al., Ophthalmol. Clin. N. Am. 15 (2002), pp. 453-458.
Borras T. et al., Experimental Eye Research 76 (2003), pp. 643-652.
Wenzel A., et al., Progress in Retinal and Eye Research 24 (2005), pp. 275-306.
Bertrand J., et al., Neurobiology of Disease (2006), doi:10.1016/j.nbd.2006.08.008.
Bertrand J., et al., The Journal of Neuroscience (2005), 25(5), pp. 1113-1121.
Flannery J. G., et al., ILAR Journal (1999), vol. 40(2).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Treatment of macular degeneration with ADP-ribosyl... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of macular degeneration with ADP-ribosyl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of macular degeneration with ADP-ribosyl... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2663175

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.